Other
21 Authors
- Que J,
- Horth C,
- Leuzzi G,
- Majewski J,
- Chen X,
- Lu C,
- Ciccia A,
- Mendelsohn CL,
- Dai E,
- Li Y,
- McGuire JT,
- Izar B,
- Goldberg EM,
- Farhangdoost N,
- Karagiannis D,
- Ailles L,
- Zhang Z,
- Yoon AJ,
- Xu X,
- Tate T,
- Li Z
| First Author | Li Y | Year | 2022 |
| Journal | Mol Cell | Volume | 82 |
| Issue | 20 | Pages | 3901-3918.e7 |
| PubMed ID | 36206767 | Mgi Jnum | J:330345 |
| Mgi Id | MGI:7378117 | Doi | 10.1016/j.molcel.2022.09.007 |
| Citation | Li Y, et al. (2022) Histone methylation antagonism drives tumor immune evasion in squamous cell carcinomas. Mol Cell 82(20):3901-3918.e7 |
| abstractText | How cancer-associated chromatin abnormalities shape tumor-immune interaction remains incompletely understood. Recent studies have linked DNA hypomethylation and de-repression of retrotransposons to anti-tumor immunity through the induction of interferon response. Here, we report that inactivation of the histone H3K36 methyltransferase NSD1, which is frequently found in squamous cell carcinomas (SCCs) and induces DNA hypomethylation, unexpectedly results in diminished tumor immune infiltration. In syngeneic and genetically engineered mouse models of head and neck SCCs, NSD1-deficient tumors exhibit immune exclusion and reduced interferon response despite high retrotransposon expression. Mechanistically, NSD1 loss results in silencing of innate immunity genes, including the type III interferon receptor IFNLR1, through depletion of H3K36 di-methylation (H3K36me2) and gain of H3K27 tri-methylation (H3K27me3). Inhibition of EZH2 restores immune infiltration and impairs the growth of Nsd1-mutant tumors. Thus, our work uncovers a druggable chromatin cross talk that regulates the viral mimicry response and enables immune evasion of DNA hypomethylated tumors. |
